A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (NCT07492680)

🧪 Interventions in This Study

• BMS-986504 (DRUG)
• Daraxonrasib (DRUG)
• Nivolumab + Relatlimab FDC (DRUG)
• Temozolomide (DRUG)
• Pumitamig (DRUG)
• Pemetrexed (DRUG)
• Carboplatin (DRUG)
• Nab-paclitaxel (DRUG)
• Gemcitabine (DRUG)
• Paclitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (57 Sites)

Showing the first 25 of 57 sites.

• Local Institution - 0096 — San Francisco, California
• Local Institution - 0182 — Aurora, Colorado
• Local Institution - 0178 — Atlanta, Georgia
• Johns Hopkins Hospital — Baltimore, Maryland
• Local Institution - 0124 — Boston, Massachusetts
• Local Institution - 0119 — Ann Arbor, Michigan
• Local Institution - 0129 — Rochester, Minnesota
• Local Institution - 0174 — Rochester, Minnesota
• Local Institution - 0181 — Rochester, Minnesota
• Local Institution - 0142 — Buffalo, New York
• Local Institution - 0170 — New York, New York
• Local Institution - 0139 — New York, New York
• Local Institution - 0100 — Durham, North Carolina
• Local Institution - 0085 — Houston, Texas
• Local Institution - 0086 — Seattle, Washington
• Local Institution - 0134 — Madison, Wisconsin
• Local Institution - 0148 — Brussels, Bruxelles-Capitale, Région de
• Local Institution - 0114 — Ghent, Oost-Vlaanderen
• Local Institution - 0051 — Vancouver, British Columbia
• Local Institution - 0021 — Toronto, Ontario
• Local Institution - 0007 — Toronto, Ontario
• Local Institution - 0155 — Beijing, Beijing Municipality
• Local Institution - 0185 — Chongqing, Chongqing Municipality
• Local Institution - 0184 — Guangzhou, Guangdong
• Local Institution - 0152 — Xinxiang, Henan

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.